| Literature DB >> 34141920 |
Tooran Nayeri1,2,3, Shahabeddin Sarvi1,2, Mehdi Sharif1,2, Ahmad Daryani1,2.
Abstract
Toxoplasma gondii (T. gondii) is one of the most pervasive neurotropic pathogens causing different lesions in a wide variety of mammals as intermediate hosts, including humans. It is estimated that one-third of the world population is infected with T. gondii; however, for a long time, there has been much interest in the examination of the possible role of this parasite in the development of mental disorders, such as Alzheimer's disease (AD). T. gondii may play a role in the progression of AD using mechanisms, such as the induction of the host's immune responses, inflammation of the central nervous system (CNS), alteration in the levels of neurotransmitters, and activation of indoleamine-2,3-dyoxigenase. This paper presents an appraisal of the literature, reports, and studies that seek to the possible role of T. gondii in the development of AD. For achieving the purpose of the current study, a search of six English databases (PubMed, ScienceDirect, Web of Science, Scopus, ProQuest, and Google Scholar) was performed. The results support the involvement of T. gondii in the induction and development of AD. Indeed, T. gondii can be considered a risk factor for the development of AD and requires the special attention of specialists and patients. Furthermore, the results of this study may contribute to prevent or delay the progress of AD worldwide. Therefore, it is required to carry out further studies in order to better perceive the parasitic mechanisms in the progression of AD.Entities:
Keywords: Alzheimer; Cytokine; Neurotransmitter; Risk factors; Toxoplasmosis
Year: 2021 PMID: 34141920 PMCID: PMC8187970 DOI: 10.1016/j.heliyon.2021.e07151
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Description of the studies included looking for an association between toxoplasmosis and AD.
| No | First author | N | Alzheimer+ (n) | Alzheimer− (n) | Alzheimer+ & T+ (n, %) | Alzheimer− & T+ (n, %) | Age (years ± SD) | Sex |
|---|---|---|---|---|---|---|---|---|
| 1 | Alvarado-Esquivel | 182 | 2 | 180 | 2 (100%) | 16 (8.9%) | P: ≥16 | P: (F:--, M:--) |
| 2 | Kusbeci | 71 | 34 | 37 | 15 (44.1%) | 9 (24.3%) | P: 68.05 ± 15.98 | P: (F:15, M:19) |
| 3 | Cong et | 478 | 33 | 445 | 5 (15.15%) | 55 (12.36%) | P: 16–91 | P: (F:--, M:--) |
| 4 | Cong et | 463 | 18 | 445 | 3 (16.66) | 55 (12.36%) | P: 16–91 | P: (F:--, M:--) |
| 5 | Menati Rashno | 174 | 87 | 87 | 58 (66.6%) | 49 (56.32%) | P: 78.17 ± 10.38 | P: (F:40, M:47) |
| 6 | Mahami-Oskouei | 150 | 75 | 75 | 46 (61.3%) | 47 (62.6%) | P: 56-93 | P: (F:41, M:34) |
| 7 | Zaki | 166 | 4 | 162 | 2 (50%) | 24 (14.8%) | P: 19-67 | P: (F:--, M:--) |
| 8 | Perry | 219 | 105 | 114 | 43 (40.95%) | 38 (33.33) | P: 80.4 ± 7.2 | P: (F:57, M:48) |
| 9 | Flegr and Horáček | 1336 | 2 | 1334 | 1 (50%) | 365 (27.36%) | M: 35.6 ± 12.4 | P: (F:2, M:0) |
AD+: individuals with Alzheimer's disease, AD−: individuals without Alzheimer's disease, AD+ & T+: individuals with Alzheimer's disease and Toxoplasma positive, AD− & T+: individuals without Alzheimer's disease and Toxoplasma positive, P: patient, C: control, F: female, M: male, N: number.
Figure 1The possible role of IFN-γ in neurogenesis in AD. IFN-γ: interferon-gamma, IDO: indoleamine 2,3-dioxygenase, KA: kynurenic acid, QA: quinolinic acid, NMDAR: N-Methyl-D-aspartic acid receptor, and α7nAChR: α7 nicotinic acetylcholine receptor.